May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Which Antibiotic Is More Consumer Friendly? The Relationship of in vitro Coverage to Cost of Antibiotics
Author Affiliations & Notes
  • P. Farhi
    Ophthalmology, UPMC, Pittsburgh, Pennsylvania
  • R. P. Kowalski
    Ophthalmology, UPMC, Pittsburgh, Pennsylvania
  • Footnotes
    Commercial Relationships P. Farhi, I own negligable shares of stocks with Wal-Mart and Target, I; R.P. Kowalski, Research support for both Allergan and Alcon, F.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 352. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Farhi, R. P. Kowalski; Which Antibiotic Is More Consumer Friendly? The Relationship of in vitro Coverage to Cost of Antibiotics. Invest. Ophthalmol. Vis. Sci. 2007;48(13):352.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To assess the correlation of in vitro efficacy with the cost of commonly used ocular antibiotics.

Methods:: 1161 bacterial conjunctivitis isolates collected between 1993 and 2005 in Campbell Laboratory, Pittsburgh, Pennsylvania, were tested for in vitro susceptibility to 11 commonly used ocular antibiotics. The average cost of each antibiotic was obtained by surveying 6 national pharmacy chains.

Results:: The percentages of susceptible isolates and the average costs of the antibiotics were: moxifloxacin (86%, $73.38), ofloxacin (86%, $46.75), ciprofloxacin (84%, $49.18), gatifloxacin (84%, $70.38), sulfacetamide (84%, $13.11), polymyxin B/trimethoprim (polytrim): (80%, $22.18), gentamicin (74%, $14.68), bacitracin (70%, $10.82), tobramycin (68%, $15.13), and erythromycin (62%, $11.17).

Conclusions:: Amongst the tested agents, sulfacetamide (a bacteriostatic antibiotic) with 84% in vitro coverage of all the isolates and an average cost of $13.11 appeared to be the most cost-effective antibiotic for empirical coverage of bacterial conjunctivitis. Although more expensive, the fluoroquinolones (bacteriocidal) appeared to provide similar coverage. Clinical experience should dictate a physician's choice of antibiotics to treat bacterial conjunctivitis.

Keywords: bacterial disease • conjunctivitis • antibiotics/antifungals/antiparasitics 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.